Tamoxifen Suppresses the Immune Response to <i>Plasmodium berghei</i> ANKA and Exacerbates Symptomatology

• Main Authors: Luis Antonio Cervantes-Candelas, Jesús Aguilar-Castro, Fidel Orlando Buendía-González, Omar Fernández-Rivera, Armando Cervantes-Sandoval, Jorge Morales-Montor, Martha Legorreta-Herrera
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Pathogens
• Subjects: malaria; <i>Plasmodium berghei</i> ANKA; tamoxifen; oestrogens; immune system
• Online Access: https://www.mdpi.com/2076-0817/10/6/743

Malaria is the most lethal parasitic disease in the world. Mortality and severity in symptoms are higher in men than women, suggesting that oestrogens, which are in higher concentration in females than in males, may regulate the immune response against malaria. Tamoxifen, a selective oestrogen receptor modulator used in breast cancer treatment due to its antagonistic effect on oestrogen receptors α and β, is also studied because of its potential therapeutic use for several parasitic diseases. However, most studies, including one in malaria, have not addressed the immunomodulatory role of tamoxifen. In this work, we evaluated the effect of tamoxifen on the immune response of CBA/Ca mice against <i>Plasmodium berghei</i> ANKA. This study showed for the first time that tamoxifen increased parasite load, aggravated symptoms by decreasing body temperature and body weight, and worsened anaemia. Additionally, tamoxifen significantly increased the splenic index and the percentages of CD4⁺ and NK⁺ cells on day eight post-infection. By contrast, tamoxifen decreased both CD8⁺ and B220⁺ populations in the spleen and decreased the serum levels of IL-2, IL-6, and IL-17. Our findings support the notion that tamoxifen is a potent immunomodulator in malaria-infected mice and suggest caution when administering it to malaria-infected women with breast cancer.